Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 50, Issue 6, Pages 623-635Publisher
WILEY
DOI: 10.1177/0091270009351879
Keywords
sergliflozin etabonate; SGLT2 inhibitor; single dose; pharmacokinetics; pharmacodynamics; type 2 diabetes mellitus
Categories
Funding
- GlaxoSmithKline
Ask authors/readers for more resources
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of sodium-dependent glucose cotransporter 2 (SGLT2). The pharmacokinetics and pharmacodynamics of sergliflozin were evaluated following single oral dose administration of sergliflozin etabonate (5-500 mg) in healthy volunteers (n = 22) and patients with type 2 diabetes mellitus (n = 8). The prodrug was rapidly and extensively converted to sergliflozin; the latter displayed linear kinetics, reached maximum plasma concentrations at similar to 30 to 45 minutes postdose (t(max)), and had a plasma elimination half-life (t(1/2)) of similar to 0.5 to 1 hour. Both prodrug and active entity showed low glomerular filtration and/or extensive renal tubular reab-sorption, with <0.5% of the administered dose being recovered in the urine. In both populations, sergliflozin etabonate produced a dose-related glucosuria under fasting conditions and following glucose loading but did not appreciably affect urinary electrolyte excretion or fluid balance. The magnitude and duration of the glucosuric effect closely paralleled plasma sergliflozin concentrations. Sergliflozin did not significantly affect fasting plasma glucose levels but produced transient attenuation of the plasma glucose AUC following glucose challenge. Single doses of sergliflozin etabonate 5 to 500 mg were well tolerated, and there were no clinically significant adverse laboratory findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available